Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

NCT ID: NCT00885664

Last Updated: 2022-08-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2010-03-31

Brief Summary

The purposes of this study are:

1. To understand whether the use of HIV therapy in persons with more advanced HIV disease results in greater side effects.

2. To determine whether these side effects can be related to greater activation of the immune system.

Detailed Description

1. To compare the incidence and severity of self-reported symptoms in persons with CD4 counts <100 cells/mm3 versus those with CD4 counts ≥ 100 cells/mm3 who are initiating antiretroviral therapy.

2. To determine the relationship between self-reported symptoms and levels of T cells, HIV RNA, activation marker cytokines including TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10 and other cytokines as measured before and after the initiation of antiretroviral therapy.

3. To determine the relationship between antiretroviral drug trough levels (estimated drug concentrations) and the incidence and severity of self-reported symptoms in persons initiating antiretroviral therapy.

4. To determine the relationship between adverse events and immunological status as evidenced by lymphocyte counts and activation marker cytokine levels.

5. To determine the relationship between clinical events and immunological status as evidenced by lymphocyte counts and activation marker cytokine levels.

Conditions

HIV Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Truvada/Kaletra CD4<100

All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\<100 cells/cu mm

Group Type: OTHER

Truvada (tenofovir/emtricitabine)

Intervention Type: DRUG

Tenofovir/emtricitabine fixed dose combination once daily

Kaletra (lopinavir/ritonavir)

Intervention Type: DRUG

Lopinavir/ritonavir 400/100 mg twice daily

Truvada/Kaletra CD4>/=100

All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\>/=100 cells/cu mm

Group Type: OTHER

Truvada (tenofovir/emtricitabine)

Intervention Type: DRUG

Tenofovir/emtricitabine fixed dose combination once daily

Kaletra (lopinavir/ritonavir)

Intervention Type: DRUG

Lopinavir/ritonavir 400/100 mg twice daily

Interventions

Truvada (tenofovir/emtricitabine)

Tenofovir/emtricitabine fixed dose combination once daily

Intervention Type: DRUG

Kaletra (lopinavir/ritonavir)

Lopinavir/ritonavir 400/100 mg twice daily

Intervention Type: DRUG

Other Intervention Names

Truvada; Kaletra

Eligibility Criteria

Inclusion Criteria

1. Age > 18 years

2. Diagnosis of HIV infection.

3. Naive to antiretroviral therapy OR no use of antiretrovirals for ≥ 6 months.

Exclusion Criteria

1. Blinded drug treatment.

2. Active untreated serious infection within 14 days of enrollment that in the opinion of the investigator would affect the subject's participation and/or safety in the study.

3. Known resistance to proposed new HIV regimen or components of regimen.

4. Requirement for drug therapy with known contraindication with proposed new antiretroviral therapy (see Prohibited and Precautionary Medications below)

5. Pregnancy or breast feeding.

6. Liver enzyme abnormalities on screening. Patients who have symptomatic Grade 3 elevations of total bilirubin, AST, ALT, or alkaline phosphatase or Grade > 3 elevations of total bilirubin, AST, ALT, or alkaline phosphatase will be excluded. Patients who have asymptomatic grade 3 elevations of total bilirubin, AST, ALT, or alkaline phosphatase may be included in the study at the discretion of the primary physician in consultation with the principal or senior investigator. Patients with grade 3 elevations of liver function tests who are co-infected with hepatitis B or hepatitis C may be included in the study at the discretion of the primary care physician in consultation with the primary or senior investigator provided that they do not have signs or symptoms of clinical hepatitis. Signs of clinical hepatitis include: icterus, abdominal tenderness and hepatosplenomegaly. Symptoms of clinical hepatitis include: fever, abdominal pain, anorexia, nausea, vomiting, fatigue, malaise, and myalgia.

7. Decreased creatinine clearance at the time of screening. Patients with a creatinine clearance of <50mL/min as calculated by the Cockcroft-Gault method should be excluded from study entry. The Cockcroft-Gault method is defined on page 33.

8. Other Grade ≥3 lab abnormalities. For any other laboratory abnormalities of grade 3 or higher, patients may be included or excluded from the study at the discretion of the primary care physician in consultation with the primary or senior investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

Gilead Sciences

INDUSTRY

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Carl J. Fichtenbaum

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Carl J Fichtenbaum, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

University of Cincinnati AIDS Clinical Trials Unit

Cincinnati, Ohio, United States

Countries

United States

Other Identifiers

IDC 30

Identifier Type: -

Identifier Source: org_study_id